

DTM Rec'd POT/PTO 22 DEC 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Application Number	Not Yet Known
--------------------	---------------

Filing Date	Herewith
-------------	----------

First Named Inventor	BIANCHI, Marco
----------------------	----------------

Art Unit	Not Yet Known
----------	---------------

Examiner Name	Not Yet Known
---------------	---------------

Attorney Docket Number	1014-PCT-US
------------------------	-------------

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	†
		Country Code* Number * Kind Code* (# known)				
B01H	2	WO 00/47104 A2	08-17-2000	PICOWER INST MED RES		
	3	WO 01/89526 A 1	11-29-2001	NORTH SHORE LONG ISLAND JEWISH RESEARCH INSTITUTE		
	9	WO 02/092004 A2	11-21-2002	NORTH SHORE LONG ISLAND JEWISH HLS. RES INST.		
	10	WO 02/074301 A1	09-26-2002	Fink Mitchell P.		
	13	WO 97/23611 A 2	07-03-1997	BULLERDIEK JOER		

3/30/06

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (02-03)

Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	Not Yet Known
Filing Date	Herewith
First Named Inventor	BIANCHI, Marco
Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	1014-PCT-US

Sheet	2	of	2
-------	---	----	---

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	PCT International Search Report for BIANCHI, et al., Int'l Application No. PCT/IT2003/000265, Filed April 29, 2003, Dated November 13, 2003.	
BDH	4	FANG, et al.; "The Significance of Changes in High Mobility Group-1 Protein mRNA Expression in Rats after Thermal Injury", Shock (Augusta, G.A.) United States APR. 2002; Vol. 17, No. 4, April 2002, Pgs. 329-333, XP009020804.	
	5	FAGES, et al.; "Regulation of Cell Migration by Amphotericin", Journal of Cell Science, Essex, GB; Vol. 113, No. 4, February 2000, Pages 611-620, XP001070170.	
	6	MULLER, et al.; "The Double Life of HMGB1 Chromatin Protein: Architectural Factor and Extracellular Signal", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) Journal; Vol. 20, No. 10, August 15, 2001, Pages 4337-4340, XP002261324.	
	7	WANG, et al.; "HMGB1 as a late Mediator of Lethal Systemic Inflammation", American Journal of Respiratory and Critical Care Medicine; Vol. 164, No. 10, Part 1, November 15, 2001, Pages 1768-1773.	
	8	WANG, et al.; "HMG-1 as a Late Mediator of Endotoxin Lethality in Mice", American Association for the Advancement of Science, U.S.; Vol. 285, July 9, 1999, Pages 248-251, XP002940163.	
	11	YANG HUAN, et al.; "HMGB1 as a Cytokine and Therapeutic Target", Journal of Endotoxin Research, Vol. 8, No. 6, Pages 460-472, XP009020930.	
BDH	12	SCAFFIDI PAOLA, et al., "Release of Chromatin Protein HMGB1 by Necrotic Cells Triggers Inflammation", NATURE (London), Vol. 418, no. 6894, July 11, 2002, Pages 191-195, XP009020930.	
	14	YANG R, et al.; "Ethyl Pyruvate Modulates Inflammatory Gene Expression in Mice Subjected to Hemorrhagic Shock", American Journal of Physiology: Gastrointestinal and Liver Physiology, American Physiological Society, U.S., Vol. 283, 2002, Pages G212-G221, XP008019310.	
	15	SIMS C A, et al.; "Ringer's Ethyl Pyruvate Solution Ameliorates Ischemia/ Reperfusion-Induced Intestinal Mucosal Injury in Rats", Critical Care Medicine, Williams and Wilkins Company, Baltimore, MA, U.S., Vol. 29, No. 8, 2001, Pages 1513-1518, XP008019328	

Examiner Signature	<i>Bruce D. Hinson</i>	Date Considered	3/30/06
--------------------	------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.